University of Minnesota Antiviral Drug Discovery Center Receives $17 Million in New Funding

Midwest AViDD Fall 2023 workshop

By Kali Kotoski, Midwest AViDD Center Program and Communications Manager

MINNEAPOLIS/ST. PAUL (10/01/2026) — The University of Minnesota’s Midwest Antiviral Drug Discovery Center has received more than $17 million in renewed funding to support the development of next-generation oral and inhalable antiviral therapeutics against endemic and emerging viral threats and to strengthen its multi-institutional, highly collaborative research program.

The renewed funding from the National Institute of Allergy and Infectious Diseases includes a recommended additional $16.89 million for Year 5, subject to the availability of funds and satisfactory progress, and builds on $66 million in funding that established the center in 2022. If Year 5 is funded as recommended, total NIH support for the Midwest Antiviral Drug Discovery (AViDD) Center will reach approximately $100 million over five years, making it one of the largest NIH-funded research awards in University of Minnesota history.

The center, headquartered in the Medical School’s Department of Pharmacology, focuses on developing broad-spectrum therapeutics against four RNA virus families, including Coronaviridae, Filoviridae, Flaviviridae, and Arenaviridae, with particular emphasis on coronaviruses, Ebola, Marburg, dengue, Lassa, and Zika viruses.

“This renewed funding will allow our center to continue optimizing lead preclinical drug candidates, discover new ones, and explore under-researched or unproven druggable targets and mechanisms that will help shape the future of antiviral drug development,” said Fang Li, a professor and endowed chair of pharmacology at the University of Minnesota Medical School and co-director of the Midwest AViDD Center. “We thank NIAID for its support and guidance and will continue to work collaboratively and in close coordination to achieve our mission.”

Among the center’s major discoveries and advances are findings that revealed how Marburg virus enters cells and showed how variant resistance can weaken clinical protease inhibitors against COVID-19; advances that moved forward a small-molecule Ebola entry inhibitor with a unique stabilizing mechanism and developed a bispecific Ebola nanobody; and discoveries that identified a promising new drug target for Zika along with a potent new class of inhibitors, and a novel class of potent, non-covalent and non-peptidic SARS-CoV-2 protease inhibitors using advanced DNA-encoded chemistry technology.

“For the majority of viruses we study, there is an absolute lack of antiviral treatment options to lessen the severity of infections,” said Reuben Harris, a Howard Hughes Medical Institute investigator, professor and chairman of the Department of Biochemistry & Structural Biology at UT Health San Antonio, and co-director of the Midwest AViDD Center. “Our remit is not only to rapidly bring drugs to the clinic, but to establish a pipeline of potential therapeutics that can be mobilized in future public health emergencies. Doing this science now will put us all in a better place in the future.”

Midwest AViDD Center Scientific Director Peter Dosa said the center’s established network has resources that would be difficult to access outside of an industry setting or at such speed.

“The depth of expertise that the center brings together is truly unique in academic drug development,” Dosa said. “From initial molecular hits through chemical optimization and preclinical pharmacokinetic studies, our center has impressive capabilities to achieve the ultimate goal of bringing life-saving treatments to the clinic.”

The Midwest AViDD Center brings together researchers from the University of Minnesota, Baylor College of Medicine, Boston University, Georgia State University, Harvard Medical School, Iowa State University, University of California, Berkeley, University of California, San Diego, University of Illinois Chicago, University of Iowa, University of Louisville, University of Tennessee Health Science Center, UT Health San Antonio, and the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology.

Share this on: